Danaher (DHR)
(Delayed Data from NYSE)
$239.60 USD
-3.65 (-1.50%)
Updated Nov 12, 2024 04:00 PM ET
After-Market: $239.58 -0.02 (-0.01%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$239.60 USD
-3.65 (-1.50%)
Updated Nov 12, 2024 04:00 PM ET
After-Market: $239.58 -0.02 (-0.01%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Zacks News
Q2 Earnings Season Scorecard and Analyst Reports for Broadcom, Oracle, & Danaher
by Sheraz Mian
Today's Research Daily features a real-time update on the Q2 earnings season and new research reports on Broadcom (AVGO), Oracle (ORCL), and Danaher (DHR).
Danaher's (DHR) Q2 Earnings & Revenues Beat, Increase Y/Y
by Zacks Equity Research
Danaher's (DHR) second-quarter 2022 revenues increase 7.4% year over year, driven by an impressive performance across its segments.
Danaher (DHR) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Danaher (DHR) delivered earnings and revenue surprises of 17.45% and 6.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate 3M (MMM) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
3M (MMM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Cost Headwinds Dampen Danaher's (DHR) Q2 Earnings?
by Zacks Equity Research
While impressive segmental performances are expected to have aided Danaher's (DHR) Q2 performance, high costs might have impeded the bottom line.
Danaher (DHR) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Danaher (DHR) closed the most recent trading day at $265.30, moving +0.58% from the previous trading session.
HTHIY vs. DHR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HTHIY vs. DHR: Which Stock Is the Better Value Option?
Danaher (DHR) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Danaher (DHR) closed at $255.51 in the latest trading session, marking a -0.98% move from the prior day.
Danaher (DHR) Stock Moves -1.77%: What You Should Know
by Zacks Equity Research
In the latest trading session, Danaher (DHR) closed at $251.88, marking a -1.77% move from the previous day.
The Zacks Analyst Blog Highlights Tesla, Broadcom, Anthem, Oracle and Danaher
by Zacks Equity Research
Tesla, Broadcom, Anthem, Oracle and Danaher have been included in this Analyst Blog.
Top Stock Reports for Tesla, Broadcom & Anthem
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), Broadcom Inc. (AVGO), and Anthem, Inc. (ANTM).
Danaher (DHR) Exhibits Bright Prospects, Headwinds Persist
by Zacks Equity Research
Danaher (DHR) gains from solid demand for its products, acquired assets and shareholder-friendly policies. However, escalating costs and high debt levels remain concerns.
Danaher (DHR) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Danaher (DHR) closed at $245.91 in the latest trading session, marking a +0.84% move from the prior day.
Danaher (DHR) Stock Moves -1.67%: What You Should Know
by Zacks Equity Research
Danaher (DHR) closed the most recent trading day at $240.85, moving -1.67% from the previous trading session.
MARUY or DHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MARUY vs. DHR: Which Stock Is the Better Value Option?
Danaher (DHR) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Danaher (DHR) closed the most recent trading day at $263.74, moving -0.87% from the previous trading session.
Why Is ITT (ITT) Down 5.5% Since Last Earnings Report?
by Zacks Equity Research
ITT (ITT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MARUY vs. DHR: Which Stock Is the Better Value Option?
by Zacks Equity Research
MARUY vs. DHR: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights Adobe, Danaher, Equinor, Advanced Micro Devices, and Automatic Data Processing
by Zacks Equity Research
Adobe, Danaher, Equinor, Advanced Micro Devices, and Automatic Data Processing are part of Zacks Top Analyst Blog.
Top Analyst Reports for Adobe, Danaher, Equinor & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Adobe Inc. (ADBE), Danaher Corporation (DHR), and Equinor ASA (EQNR).
Top Analyst Reports for Alphabet, Amazon & Chevron
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Amazon.com, Inc. (AMZN), and Chevron Corporation (CVX).
All You Need to Know About Danaher (DHR) Rating Upgrade to Buy
by Zacks Equity Research
Danaher (DHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Danaher's (DHR) Q1 Earnings & Revenues Beat, Increase Y/Y
by Zacks Equity Research
Danaher's (DHR) first-quarter 2022 revenues increase 12% year over year driven by impressive performance across its segments.
Danaher (DHR) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Danaher (DHR) delivered earnings and revenue surprises of 4.15% and 1.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights UnitedHealth Group, Danaher, Wells Fargo, Vertex Pharmaceuticals and Canadian Pacific Railway
by Zacks Equity Research
UnitedHealth Group, Danaher, Wells Fargo, Vertex Pharmaceuticals and Canadian Pacific Railway have been included in this Analyst Blog.